Michal Zimmermann

Company: Repare Therapeutics

Job title: Associate Director of Cancer Biology

Seminars:

ATRi Development & Biomarker-Led Selection; Bridging the Gap Between the Lab & the Clinic 9:00 am

Functional genomic screening informs patient selection for biomarker-driven clinical trials of ATR inhibitors (and beyond) Identification of sensitive genetic backgrounds may mitigate known challenges with administering ATR and PARP inhibitor combinations Mechanistic insights lead to development of optimized dosing schedules for ATR inhibitors and their combinationsRead more

day: Day Two